Alkem Labs acquires anti-nausea drug Marinol from AbbVie for $10 million
Tuesday, December 31, 2019, 8:10 PM
Alkem Laboratories on December 31 announced that it is acquiring anti-nausea drug Marinol from US drug maker AbbVie for $10 million. Marinol, generically called as Dronabinol, is a man-made or synthetic form of marijuana (cannabis). Marinol capsules are used to treat the loss of appetite (anorexia) in AIDS patients and to treat nausea and vomiting in patients receiving chemotherapy.